Articles From: Agilent Technologies to Present at 32nd Annual J.P. Morgan Healthcare Conference to Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration


2014/1/3
Agilent Technologies Inc. (NYSE: A) today announced the following webcast for the investment community: 32 nd Annual J.P. Morgan Healthcare Conference About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications.
Sign-up for Agilent Technologies to Present at 32nd Annual J.P. Morgan Healthcare Conference investment picks
Agilent Technologies Inc. (NYSE: A) today announced the following webcast for the investment community: About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications.
Sign-up for Agilent Technologies to Present at Morgan Stanley Global Healthcare Conference investment picks
2013/12/9
Agilent Technologies Inc. (NYSE:A) today announced it will host two life science workshops in California this month.
Sign-up for Agilent Technologies to Sponsor Life Science Workshops in San Diego, San Francisco Bay Area on Dec. 11 and 12 investment picks
2014/3/17
Agilent Technologies Inc. (NYSE: A) today announced its support for a new international research consortium, led by the National University of Singapore (NUS), that aims to develop the world’s first lipid 1 database for healthy persons of different racial and ethnic groups.
Sign-up for Agilent Technologies to Support National University of Singapore-Led Research Consortium to Identify, Map Lipid Levels in Healthy People investment picks
SAN FRANCISCO (MarketWatch) - Technology stocks were mostly higher Thursday, as shares of Agilent Technologies, Groupon Inc. and AOL Inc. rallied at the opening bell.
Sign-up for Agilent, Groupon rally; Oracle, Cisco slip investment picks
2014/2/13
SAN FRANCISCO (MarketWatch) -- Agilent Technologies Inc. (A) on Thursday reported a fiscal first-quarter profit of $195 million, or 58 cents a share, compared with earnings of $179 million, or 51 cents a share, in the year-ago period.
Sign-up for Agilentm earnings rise 9%, but sales are flat investment picks
Exclusive Channel Collaboration Focused on DNA-based Therapeutics for Children and Adults with Friedreich's ataxia NEW YORK and GERMANTOWN, Md.
Sign-up for Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease investment picks
Agility Multichannel, an award-winning provider of product information management (PIM) software for multichannel commerce, today announced that it has become a Demandware LINK Technology Partner, joining a best-of-breed community committed to accelerating the adoption of innovative commerce technologies that are complementary to the Demandware® Commerce platform.
Sign-up for Agility Multichannel Joins Demandware LINK to Accelerate Commerce Innovation investment picks
Agilysys, Inc. (Nasdaq: AGYS), a leading provider of innovative information technology and hospitality software and services, today announced general availability of Agilysys InfoGenesis™ Mobile v2.0, a full-featured mobile point-of-sale application that integrates seamlessly with the Agilysys InfoGenesis POS system.
Sign-up for Agilysys Announces Availability of InfoGenesis™ Mobile v2.0 investment picks
Agilysys, Inc. (Nasdaq: AGYS), a leading provider of innovative information technology and hospitality software and services, today announced general availability of the Agilysys Insight™ Mobile Manager application.
Sign-up for Agilysys Announces Availability of Insight™ Mobile Manager Solution investment picks
2013/8/13
Agilysys, Inc. (Nasdaq: AGYS) , a leading provider of innovative information technology and hospitality software and services, today announced the general availability of SWSDirect , an add-on module that delivers new features and functionality to the company's Stratton Warren System (SWS) inventory and procurement solution.
Sign-up for Agilysys Announces Availability of SWSDirect investment picks
2014/2/18
Agilysys, Inc. (Nasdaq: AGYS), a leading provider of innovative hospitality software solutions and services, today announced the release of the Agilysys Visual One™ PMS v8.51. The latest version of the property management solution features significant architectural improvements that enable quick application deployment, more robust functionality and numerous integration benefits.
Sign-up for Agilysys Announces Release of Visual One™ PMS v8.51 investment picks
Agilysys, Inc. (Nasdaq: AGYS) , a leading provider of innovative information technology and hospitality software, services and solutions, today announced the promotion of Janine Seebeck, to the role of senior vice president, chief financial officer and treasurer, effective immediately.
Sign-up for Agilysys Appoints Janine Seebeck Chief Financial Officer investment picks
2014/1/16
Agilysys, Inc. (Nasdaq: AGYS), a leading provider of innovative hospitality software solutions and services, today announced InfoGenesis Flex , a new mobility solution that offers full point-of-sale functionality on the Lenovo ThinkPad 2 tablet.
Sign-up for Agilysys Introduces Innovative Mobility Option for InfoGenesis™ POS investment picks
2014/1/30
Agilysys, Inc. (Nasdaq:AGYS) , a leading developer and provider of innovative software enabled solutions for the hospitality industry, today reported operating results for its fiscal 2014 third quarter.
Sign-up for Agilysys Reports Third Quarter Revenue of $26.0 Million Inclusive of 11% Growth in Recurring Revenue to $13.6 Million investment picks
2014/3/31
Agilysys, Inc. (Nasdaq:AGYS), a leading provider of innovative hospitality software solutions and services, today announced the sale of its United Kingdom business entity to U.K.-based Verteda Limited.
Sign-up for Agilysys Sells Majority of the United Kingdom Business and Enters Into Multi-Year EMEA Market Distribution Agreement investment picks
2013/10/23
Agilysys, Inc. (Nasdaq: AGYS) , a leading developer and provider of innovative information technology, services and solutions for the hospitality industry, announced today that it will release its fiscal 2014 second quarter results before the market opens on Thursday, November 7, 2013, and will host a conference call and webcast at 8:30 a.m. ET on Thursday, November 7.
Sign-up for Agilysys to Report Fiscal 2014 Second Quarter Results on November 7 and Host Conference Call and Webcast investment picks
2014/1/16
Agilysys, Inc. (Nasdaq:AGYS) , a leading developer and provider of innovative information technology and hospitality software and services, announced today that it will release its fiscal 2014 third quarter results after the market closes on Thursday, January 30, and will host a conference call and webcast at 4:30 p.m. ET on Thursday, January 30.
Sign-up for Agilysys to Report Fiscal 2014 Third Quarter Results on January 30 and Host Conference Call and Webcast investment picks
Agilysys, Inc. (Nasdaq: AGYS) , a leading developer and provider of innovative information technology and hospitality software and services, announced today the appointment, effective immediately, of Michael Buckham-White to the position of Senior Vice President of Sales and Marketing.
Sign-up for Agilysys Unifies Global Sales and Marketing Activities with Appointment of Michael Buckham-White as SVP Sales and Marketing investment picks
2013/11/7
Agilysys, Inc. (Nasdaq: AGYS) , a leading developer and provider of innovative software enabled solutions for the hospitality industry, today reported operating results for its fiscal 2014 second quarter.
Sign-up for Agilysys’ Second Quarter Revenue Increases 10% to $26.6 Million; Company Reports Adjusted and GAAP Earnings Per Diluted Share from Continuing Operations of $0.03 and $(0.03), Respectively investment picks
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced an extension of one additional year to the period of exclusivity for their strategic cancer metabolism collaboration with Celgene Corporation (NASDAQ: CELG). “The quality of the scientific interaction and collaboration with Agios has been outstanding,” said Thomas Daniel, M.D., president of research for Celgene.
Sign-up for Agios Advances Cancer Metabolism Collaboration with Celgene investment picks
2014/3/31
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that preclinical and clinical data from Agios’ cancer metabolism programs will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-9, 2014 in San Diego, Calif.
Sign-up for Agios Announces Clinical and Preclinical Data to be Presented at AACR Annual Meeting 2014 investment picks
2014/3/19
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the first patient has been dosed in a Phase 1 study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 (IDH1) mutation.
Sign-up for Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation investment picks
2014/4/6
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, announced that data from its lead, first-in-class program AG-221 will be presented today at a Clinical Trials Symposium titled “Novel Immune and Targeted Therapies for Hematological Malignancies and Solid Tumors” at the American Association for Cancer Research (AACR) Annual Meeting 2014.
Sign-up for Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers investment picks
2014/3/24
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.
Sign-up for Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation investment picks
2013/12/23
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), active prior to market open today.
Sign-up for Agios Pharmaceuticals Added to NASDAQ Biotechnology Index investment picks
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that the company has been added to the Russell 2000®, Russell 3000® and Russell Global® Indexes as part of Russell Investments’ third-quarter IPO additions that took place after market close on September 30, 2013.
Sign-up for Agios Pharmaceuticals Added to Russell 2000®, 3000® and Global Indexes investment picks
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), today announced the addition of Paul J.
Sign-up for Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors investment picks
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced dose administration for the first patient in a Phase 1 study of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation.
Sign-up for Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221 in Advanced Hematologic Malignancies with an IDH2 Mutation investment picks
2014/2/3
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, announced today that it has elected to retain the United States development and commercial rights to the isocitrate dehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism.
Sign-up for Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Agilent Technologies to Present at 32nd Annual J.P. Morgan Healthcare Conference to Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity